LDLR-Targeted siRNA Conjugates for Ocular Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering interfering RNA molecules in vivo are inefficient and lack specificity, leading to off-target effects and immune responses, limiting their therapeutic potential for treating ocular disorders.
Innovation Solution
Development of interfering RNA molecule-ligand conjugates that bind to the low density lipoprotein receptor (LDLR) or LDLR family members, facilitating targeted delivery of interfering RNA into cells, including ocular cells, using various ligands such as peptides and antibodies, and administration methods like intraocular injection or topical application.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If interfering RNA is delivered using conventional methods (naked siRNA, polycations, cationic lipids, or liposomes), then delivery can be achieved, but the delivery efficiency is low and off-target effects occur
Solution Approach 1:
The patent uses LDLR-targeting ligands as intermediaries to mediate the delivery of interfering RNA to ocular tissues. The ligand acts as a bridge that specifically binds to LDLR on ocular cells, enabling targeted delivery while reducing off-target effects. This is achieved by conjugating the interfering RNA with ligands such as apoE, apoB-100, or their peptide mimics that have high affinity for LDLR.
Solution Approach 2:
The patent modifies the chemical parameters of the interfering RNA by conjugating it with LDLR-targeting ligands. This chemical modification changes the delivery characteristics, enabling receptor-mediated endocytosis and improving both delivery efficiency and targeting specificity to ocular tissues while reducing systemic off-target effects.
2Adaptability or versatility
If interfering RNA is delivered systemically, then broad distribution is achieved, but specificity to ocular tissues is lost
Solution Approach 1:
The patent imparts local quality to the interfering RNA delivery system by conjugating it with LDLR-targeting ligands that specifically recognize ocular tissues. This creates a delivery system with heterogeneous properties: the ligand portion provides tissue-specific targeting to ocular LDLR, while the interfering RNA portion provides the therapeutic function. This local quality enhancement enables selective accumulation in ocular tissues even after systemic administration.
Solution Approach 2:
The LDLR-targeting ligand serves as an intermediary that confers tissue-specific targeting capability to the interfering RNA. Ligands such as apoE and apoB-100, or their peptide mimics, act as mediators that guide the conjugate to ocular tissues expressing LDLR, thereby achieving both systemic delivery and local specificity.
3Productivity
If high doses of interfering RNA are administered to overcome delivery inefficiency, then therapeutic effect may be achieved, but immune responses are triggered
Solution Approach 1:
The LDLR-targeting ligand conjugate acts as an intermediary delivery vehicle that enables efficient cellular uptake of interfering RNA through receptor-mediated endocytosis. This targeted delivery mechanism improves therapeutic efficacy at lower doses, thereby avoiding the immune responses that would be triggered by high-dose administration of naked or conventionally delivered interfering RNA.
4Device complexity
If conventional delivery methods are used, then simplicity is maintained, but delivery mechanism lacks specificity
Solution Approach 1:
The patent introduces LDLR-targeting ligands as specific intermediaries that bind to LDLR on ocular cells. This adds a targeting layer to the delivery mechanism, where the ligand portion provides specificity through receptor binding, while the interfering RNA portion provides the therapeutic function. Examples of such ligands include apoE, apoB-100, and their peptide mimics.
Solution Approach 2:
The patent creates a composite delivery system by conjugating interfering RNA with LDLR-targeting ligands. This composite structure combines the therapeutic function of interfering RNA with the targeting capability of the ligand, resulting in a conjugate that exhibits both cellular uptake efficiency and tissue-specific targeting to ocular tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhanced cellular uptake and specificity of interfering RNA, reducing off-target effects and immune responses, allowing for effective attenuation of target gene expression in ocular tissues, thereby treating or preventing ocular disorders like angiogenesis, dry eye, and glaucoma.
Implementation Method 1
the conjugates comprise an interfering RNA molecule and a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member
Data Source
AI summary
The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.